Trials / Unknown
UnknownNCT06200363
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
A Clinical Study of Intravenous MVR-T3011 (T3011) in Combination With Oral Regorafenib in Patients With Advanced Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of advanced colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T3011 | T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle. |
| DRUG | Regorafenib | Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance. |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2024-01-11
- Last updated
- 2024-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06200363. Inclusion in this directory is not an endorsement.